Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/sk-hep-cells-and-lentiviral-vector-for-production-of-human-recombinant-BodtSPHldY
References (20)
-
K Garber (2000)
rFactor VIII deficit questionedNat Biotechnol, 18
-
SC Heffelfinger, HH Hawkins, J Barrish, L Taylor, GJ Darlington (1992)
SK HEP-I: a human cell line of endothelial originIn Vitro Cell Dev Biol, 28
-
EMS Russo-Carbolante, V Picanço-Castro, DCC Alves, AC Fernandes, G Almeida-Porada, T Tonn, DT Covas (2011)
Integration pattern of HIV-1 based lentiviral vector carrying recombinant coagulation factor VIII in SK-HEP and 293T cellsBiotechnol Lett, 33
-
L Grillberger, TR Kreil, S Nasr, M Reiter (2009)
Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cellsBiotechnol J, 4
-
M Nishikawa, L Huang (2001)
Nonviral vectors in the new millennium: delivery barriers in gene transferHum Gene Ther, 12
-
C Chen, XD Fang, J Zhu, XF Wu, ZC Zhang, JX Gu, ZY Wang, CW Chi (1999)
The gene expression of coagulation factor VIII in mammalian cell linesThromb Res, 95
-
Q Shi, DA Wilcox, SA Fahs, PA Kroner, RR Montgomery (2003)
Expression of human factor VIII under control of the platelet-specific aIIb promoter in megakaryocytic cell line as well as storage together with VWFMol Genet Metab, 79
-
SE Herlitschka, U Schlokat, FG Falkner, F Dorner (1998)
High expression of a B-domain deleted factor VIII gene in a human hepatic cell lineJ Biotechnol, 61
-
LW Hoyer (1994)
Hemophilia AN Engl J Med, 330
-
SA Stonebracker, M Brooker, RE Amand, A Farrugia, A Srivastava (2010)
A study of reported factor VIII use around the worldHaemophilia, 16
-
T Tharmalingam, K Sunley, M Butler (2008)
High yields of monomeric recombinant beta-interferon from macroporous microcarrier cultures under hypothermic conditionsBiotechnol Prog, 24
-
HT Spencer, G Denning, RE Gautney, B Dropulic, AJ Roy, L Baranyi, B Gangadharan, ET Parker, P Lollar, CB Doering (2011)
Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIIIMol Ther, 19
-
CM Lynch, DI Israel, RJ Kaufman, AD Miller (1993)
Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein productionHum Gene Ther, 4
-
KL Dooriss, G Denning, B Gangadharan, EH Javazon, DA McCarty, HT Spencer, CB Doering (2009)
Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia AHum Gene Ther, 20
-
J Mordenti, G Osaka, K Garcia, K Thomsen, V Licko, G Meng (1996)
Pharmacokinetics and interspecies scaling of recombinant human factor VIIIToxicol Appl Pharmacol, 136
-
V Picanco, S Heinz, D Bott, M Behrmann, DT Covas, E Seifried, T Tonn (2007)
Recombinant expression of coagulation factor VIII in hepatic and non-hepatic cell lines stably transduced with third generation lentiviral vectors comprising the minimal factor VIII promoterCytotherapy, 9
-
V Picanco-Castro, EMS Russo-Carbolante, AM Fontes, AC Fernandes, DT Covas (2008)
An enhancer/promoter combination strengthens the expression of blood-coagulation factor VIII in non-viral expression vectorsGenet Mol Res, 7
-
JM Soucie, B Evatt, D Jackson (1998)
Occurrence of hemophilia in the United States. The hemophilia surveillance system project investigatorsAm J Hematol, 59
-
Y Durocher, M Butler (2009)
Expression systems for therapeutic glycoprotein productionCurr Opin Biotechnol, 20
-
B Mei, Y Chen, J Chen, CQ Pan, JE Murphy (2006)
Expression of human coagulation factor VIII in a human hybrid cell line, HKB11Mol Biotechnol, 34
- Publisher
- Springer Journals
- Copyright
- Copyright © 2012 by Springer Science+Business Media B.V.
- Subject
- Life Sciences; Microbiology; Biochemistry, general; Applied Microbiology; Biotechnology
- ISSN
- 0141-5492
- eISSN
- 1573-6776
- DOI
- 10.1007/s10529-012-0925-4
- pmid
- 22488441
- Publisher site
- See Article on Publisher Site
Abstract
Hemophilia A is caused by a deficiency in coagulation factor VIII. Recombinant factor VIII can be used as an alternative although it is unavailable for most patients. Here, we describe the production of a human recombinant B-domain-deleted FVIII (rBDDFVIII) by the human cell line SK-HEP-1, modified by a lentiviral vector rBDDFVIII was produced by recombinant SK-HEP cells (rSK-HEP) at 1.5–2.1 IU/106 in 24 h. The recombinant factor had increased in vitro stability when compared to commercial pdFVIII. The functionality of rBDDFVIII was shown by its biological activity and by tail-clip challenge in hemophilia A mice. The rSK-HEP cells grew in a scalable system and produced active rBDDFVIII, indicating that this platform production can be optimized to meet the commercial production scale needs.
Journal
Biotechnology Letters – Springer Journals
Published: Apr 10, 2012